Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs GlobeNewswire - Thu Dec 11, 3:01PM CST

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants GlobeNewswire - Tue Dec 9, 10:15PM CST

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants GlobeNewswire - Mon Dec 8, 3:01PM CST

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron GlobeNewswire - Mon Dec 8, 7:00AM CST

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight...

GPCR : 67.06 (-0.56%)
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 GlobeNewswire - Sun Dec 7, 5:20PM CST

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights GlobeNewswire - Thu Nov 6, 3:01PM CST

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)...

GPCR : 67.06 (-0.56%)
Piper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR) Tipranks - Sat Oct 4, 7:10AM CDT

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $93.00. The company’s shares closed yesterday at $26.62.Elevate...

GPCR : 67.06 (-0.56%)
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences GlobeNewswire - Tue Sep 2, 7:30AM CDT

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights GlobeNewswire - Wed Aug 6, 3:01PM CDT

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to...

GPCR : 67.06 (-0.56%)
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 GlobeNewswire - Fri Jun 20, 6:30PM CDT

GPCR : 67.06 (-0.56%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - 31 minutes ago
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot